GlassScriptPhysician profile
Laura B Baker
NPI 1417213729
$6,683.78
in general payments reported to CMS, 2019-2025
26 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $1,420 · 2023: $1,456 · 2024: $1,078 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,724 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,723.80 |
| Education | $257.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,536.12 | 2021-2025 | |
| Janssen Biotech, INC. | $1,333.06 | 2021-2025 | Tremfya |
| Ucb, INC. | $1,099.89 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $530.07 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $322.52 | 2022-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $256.99 | 2021-2025 | |
| Leo Pharma INC. | $239.63 | 2022-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $204.09 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Lilly USA, LLC | $154.18 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $153.87 | 2021-2025 | Dupixent, Libtayo |
| Glaxosmithkline, LLC. | $122.09 | 2022 | |
| Genzyme Corporation | $121.05 | 2021-2025 | |
| Pfizer INC. | $106.22 | 2021-2023 | |
| Incyte Corporation | $87.58 | 2021-2025 | Opzelura |
| Mallinckrodt Hospital Products INC. | $86.03 | 2025 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $55.97 | 2023 | Otezla |
| Organon LLC | $39.55 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $38.15 | 2021 | |
| Neurocrine Biosciences, INC. | $36.55 | 2023-2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $31.34 | 2022-2023 | Keytruda |
| Dermavant Sciences, INC. | $29.70 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.65 | 2023 | Cyltezo |
| Organogenesis INC. | $23.24 | 2021 | |
| Galderma Laboratories, L.P. | $20.40 | 2025 | Nemluvio |
| Kyowa Kirin, INC. | $17.08 | 2021 | |
| Journey Medical Corporation | $14.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.